The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent “in-tumour” chemotherapy to pancreatic ductal adenocarcinoma
Taken together these data provide the preclinical rationale for combined Ad5<sub>NULL</sub>-A20.FCU1 plus 5-FC as a promising targeted therapy to mediate "in-tumour chemotherapy" and merits further investigation for the treatment of PDAC patients.
Authors
- James A. Davies
- Valérie S. Méniel
- Mahulena Marušková
- Luned Badder
- Toby J. Phesse (ORCID: https://orcid.org/0000-0001-9568-4916)
- Alan L. Parker (ORCID: https://orcid.org/0000-0002-9302-1761)
- Catherine Hogan (ORCID: https://orcid.org/0000-0002-1012-0896)
- Beatriz Salvador-Barberó (ORCID: https://orcid.org/0000-0003-3842-2383)
- Rebecca Bayliss (ORCID: https://orcid.org/0000-0002-3324-957X)
Institutions
- The University of Melbourne (AU)
- Peter Doherty Institute (AU)
- Cardiff University (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1038/s41416-024-02869-3
- Citations
- 2
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- Cancer Research Wales
- Cancer Research UK
- Higher Education Funding Council for Wales